Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Synthekine, Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 2 distinct art units. The presence of 2 distinct art units indicates that the portfolio's subject matter is diverse enough to trigger different specialized reviews within the patent office. This distribution requires a prosecution strategy that can adapt to the varying standards of multiple examination groups.
REDDIG, PETER J is the busiest examiner for this portfolio, currently overseeing 1 pending office action. With 3 distinct examiners each handling a portion of the 3 pending actions, the workload is distributed evenly across the examining staff. This distribution suggests that the practitioner must manage three separate examiner relationships simultaneously. Because the 3 pending office actions are not concentrated under a single examiner, the company must ensure consistency in its arguments across the 2 distinct art units. This level of activity in the biotechnology sector highlights a multi-faceted approach to securing intellectual property rights, where each of the 3 distinct examiners provides a unique hurdle in the path toward allowance.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 49d overdue |
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 49d overdue |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | ALLEN, MARIANNE P | 9d overdue |
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — | §101§102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 1643 | §102§103 | Final Rejection | 49d overdue | Pending | Jul 07, 2023 |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 9d overdue | Pending | Feb 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial